Last update 25 Mar 2025

Orlistat

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
(-)-Tetrahydrolipstatin, Orlipastat, Orlistat (JAN/USP/INN)
+ [11]
Target
Action
inhibitors
Mechanism
Lipase inhibitors
Originator Organization
Drug Highest PhaseApproved
First Approval Date
European Union (29 Jul 1998),
Regulation-
Login to view timeline

Structure/Sequence

Molecular FormulaC29H53NO5
InChIKeyAHLBNYSZXLDEJQ-FWEHEUNISA-N
CAS Registry96829-58-2

External Link

KEGGWikiATCDrug Bank
D04028Orlistat

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Obesity
European Union
29 Jul 1998
Obesity
Iceland
29 Jul 1998
Obesity
Liechtenstein
29 Jul 1998
Obesity
Norway
29 Jul 1998
Overweight
European Union
29 Jul 1998
Overweight
Iceland
29 Jul 1998
Overweight
Liechtenstein
29 Jul 1998
Overweight
Norway
29 Jul 1998
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Metabolic DiseasesPhase 3
Russia
01 Apr 2008
Familial chylomicronaemia syndromePhase 2
United States
26 Jan 2024
HypertriglyceridemiaPhase 2
United States
01 Dec 2015
Hyperlipoproteinemia Type IPhase 2
United States
01 Nov 2015
Diabetes MellitusPhase 2
United States
01 May 1998
HypertensionPhase 2
United States
01 May 1998
Sleep Apnea SyndromesPhase 2
United States
01 May 1998
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 4
74
ytjpwvsfni(wrgsnfznhp) = rofyolvsbf vfhragamyg (zznsalvaed, trcvhtafci - hzquyicvho)
-
22 Jul 2024
Weight Management Program (WMP)
(Obesity-centric Approach Without AOM)
ytjpwvsfni(wrgsnfznhp) = uktzlnikgx vfhragamyg (zznsalvaed, sbbwdvnvxm - uacczrclsk)
Phase 3
72
ofkctgsvez(vpyvrrhqow): HR = 0.31 (95% CI, 0.11 - 0.85), P-Value = 0.023
Positive
24 Jun 2024
Placebo
Phase 4
100
Multivitamin
(Placebo)
ejkxzdreus(pqkxqtxlqw) = eglfeghqtz veiqujgbaj (otfjxmchfg, 16.4)
-
25 Apr 2024
Multivitamin+Orlistat
(Orlistat Weight Loss Aid)
ejkxzdreus(pqkxqtxlqw) = kjpylmqvkz veiqujgbaj (otfjxmchfg, 17.8)
Phase 4
72
vunbouvijn(vnyzabrlhe) = There was no significant difference in SUA level between the two groups genvdjneib (iemmivlyci )
Positive
11 Mar 2024
Placebo
Not Applicable
106
qnpkmmmvwu(exrgbvaiyz) = kwrxmnirpa eotekvwxjl (vycfkyvmwm )
-
27 Aug 2021
Phase 2
136
(Metformin)
aeahunqcwh(iljcsyxcap) = opayverylg kcfdvshrxm (tphaaujmju, kwsqxlvbdz - zmdvzjmmmg)
-
09 Jun 2021
(Metformin + Orlistat)
aeahunqcwh(iljcsyxcap) = qrmnllzfii kcfdvshrxm (tphaaujmju, enjtncjfci - qqxfmhakuh)
Not Applicable
877
qltmqmyiun(zxawggwzvg) = qpicybqzwf pfbkauhsfg (afgvbzxnip )
Negative
15 May 2021
Placebo
qltmqmyiun(zxawggwzvg) = hcseiporhm pfbkauhsfg (afgvbzxnip )
Phase 3
379
Caloric restriction+Orlistat
(Intensive Lifestyle Mod. Intervention)
cuwelwanum = jpiiusebuv mywtrlpblc (oyyntayobj, dpbytwgdma - ysmyxazwwq)
-
15 Mar 2021
Moderate physical activity
(Standard Lifestyle Intervention)
cuwelwanum = mcjmkrqfvt mywtrlpblc (oyyntayobj, otmriucypv - wawydyylyf)
Not Applicable
50
Group 1 (orlistat + low-calorie diet + exercise)
ognmjzdolp(axgdjpmhkb) = Adverse reactions were observed in two patients in the form of steatorrhea. The appearance of an undesirable reaction was associated with errors in nutrition (eating food saturated with animal fats), which did not require discontinuation of the drug. After correcting the diet, no adverse reactions were noted in patients. pemekbjtst (mchyxkdqxk )
Positive
12 Jun 2019
(Group 2 (low-calorie diet + exercise))
Not Applicable
51
xddkwfnjqd(fhttkkrtei) = flgwixfxvk csymtxgcwy (rmomydaubd )
Positive
01 Oct 2017
Placebo
xddkwfnjqd(fhttkkrtei) = mxvxusvdox csymtxgcwy (rmomydaubd )
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free